Long-term follow-up of a Phase III Study of ch14.18 (Dinutuximab) + Cytokine Immunotherapy in Children with High-risk Neuroblastoma: Children’s Oncology Group Study ANBL0032

PURPOSE: Previously our randomized Phase III trial demonstrated that immunotherapy including dinutuximab, a chimeric anti-GD2 monoclonal antibody, granulocyte macrophage-colony stimulating factor (GM-CSF), and interleukin-2 (IL2) improved survival for children with high-risk neuroblastoma that had r...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Clin Cancer Res
Autors principals: Yu, Alice L., Gilman, Andrew L., Ozkaynak, M. Fevzi, Naranjo, Arlene, Diccianni, Mitchell B., Gan, Jacek, Hank, Jacquelyn A., Batova, Ayse, London, Wendy B., Tenney, Sheena C., Smith, Malcolm, Shulkin, Barry L., Parisi, Marguerite, Matthay, Katherine K., Cohn, Susan L., Maris, John M., Bagatell, Rochelle, Park, Julie R., Sondel, Paul M.
Format: Artigo
Idioma:Inglês
Publicat: 2021
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC8046731/
https://ncbi.nlm.nih.gov/pubmed/33504555
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-20-3909
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars